


Supplementary Fig. S6 SYRCLE's risk of bias scores of animal studies: three studies.¹⁻³



References

1. da Silva A, et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. *Leuk Lymphoma*. 2014;55(7):1609-17.
2. Ryan AM, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®). *Toxicol Pathol*. 2014;42(7):1069-81.
3. Hurst S, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin®). *BioDrugs*. 2014;28(5):451-9.